All News

AUA paid tribute to outstanding health journalism by presenting the first Excellence in Urology Health Reporting Awards at a press reception yesterday. Eric T. Rosenthal received the Trade Press award for his Oncology Times article, "Prostate Cancer: Pros and Cons of the Integration of Urology and IMRT Services in the Community Practice." MSNBC reporter Michael Stuckey took the Consumer Broadcast award for his series, "Low Blow: One Man's Battle with Prostate Cancer."

The oncoFISH Bladder robotic digital microscopy system from Ikonisys (New Haven, CT) identifies and measures aneuploidy on chromosomes 3, 7, 9, and 17 in urine sediment specimens for diagnosis of initial and recurrent bladder cancer. Up to 170 prepared slides can be loaded, scanned, and the images captured in this walkaway system, which generates a gallery of images for review and interpretation. Select slide images and the analytical report can be transmitted to the urologist within 24 hours for diagnosis.

Americans spend almost $11 billion annually in medical care related to urologic diseases, and Medicare's share of the bill was $5.4 billion, according to a 5-year project issued by the National Institutes of Health that is now available in print and on CD.

Preliminary results from the REDUCE (REduction by DUtasteride of prostate Cancer Events) trial suggest a relationship between the degree of chronic inflammation and LUTS, but not clinical prostatitis-like symptoms in the REDUCE population. Also, men with more severe LUTS are more likely to experience pelvic pain as part of their symptom complex, according to the study findings presented here yesterday.

It appears that ureteroscopy and other minimally invasive techniques, such as laser lithotripsy, are safe and effective in managing pediatric nephrolithiasis, including ureteric calculi, renal pelvic stones, and lower-pole stones.

The use of cryoablation, rather than radiofrequency (RF) ablation for the treatment of small renal masses may be controversial for some urologists, but recent data support the superiority of cryoablation.

The concept of physicians demanding and getting stipends for being on call at hospital emergency rooms is becoming a well-established trend that many feel will eventually reach into all hospitals. Urologists are no exception.

The mainstay of treatment for men with metastatic prostate cancer, gonadotropin-releasing hormone (GnRH) agonists are also the subject of recent studies showing that they raise the risk of such adverse effects as diabetes and cardiovascular disease.

Developments in stem cell therapy, new minimally invasive sling procedures, and research on botulinum toxin (Botox) therapy for overactive bladder soon will give urologists far more effective treatment for incontinence than they can offer their patients today.

A baseline bone density test to screen for osteoporosis, simple lifestyle changes to prevent osteoporosis from developing, and aggressive treatment if it develops are strongly recommended for men on androgen deprivation therapy (ADT) for advanced prostate cancer.

Basic research should soon bring urologists entirely new ways to thwart or treat urinary tract infection, which could be welcome eleventh-hour saves from the problem of antibiotic-resistant bacteria.